Advertisement
Screener

OncoMed Pharmaceuticals Inc Patents: Applications Rejected

OncoMed Pharmaceuticals Inc Patent Applications Rejected

50 applications abandoned without a patent; the status gives the reason, newest filing first, as the USPTO Open Data Portal records them; the company is the first-named applicant. The application number opens the full record at Patent Center.

  • 2021-05-26: Application 17330716; Invention COMBINATION THERAPY FOR TREATMENT OF DISEASE; Applicant OncoMed Pharmaceuticals, Inc; Status Abandoned -- Failure to Respond to an Office Action.
  • 2018-08-29: Application 16116036; Invention VEGF/; Applicant OncoMed Pharmaceuticals, Inc.; Status Abandoned -- Failure to Respond to an Office Action.
  • 2018-08-24: Application 16111841; Invention Compositions and Methods for Diagnosing and Treating Cancer; Applicant OncoMed Pharmaceuticals, Inc.; Status Abandoned -- Failure to Respond to an Office Action.
  • 2018-08-23: Application 16079180; Invention REDIRECTING IMMUNE RESPONSES; Applicant OncoMed Pharmaceuticals, Inc.; Status Abandoned -- Incomplete Application (Pre-examination).
FiledApplicationInventionApplicantStatusPublished asInventor nameInventor countryExaminer
2021-05-2617330716COMBINATION THERAPY FOR TREATMENT OF DISEASEOncoMed Pharmaceuticals, IncAbandoned -- Failure to Respond to an Office ActionUS20210403553A1
Christopher Lamond Murriel
Timothy Charles Hoey
Austin L. Gurney
Julie Michelle Roda
Minu K. Srivastava
Inkyung Park
Jakob Dupont
United States
United States
United States
United States
United States
United States
United States
BUNNER, BRIDGET E
2018-08-2916116036VEGF/DLL4 BINDING AGENTS AND USES THEREOFOncoMed Pharmaceuticals, Inc.Abandoned -- Failure to Respond to an Office ActionUS20190062424A1
Austin L. GURNEY
Aaron Ken SATO
Christopher John BOND
United States
United States
United States
LOCKARD, JON MCCLELLAND
2018-08-2416111841Compositions and Methods for Diagnosing and Treating CancerOncoMed Pharmaceuticals, Inc.Abandoned -- Failure to Respond to an Office ActionUS20190060453A1
Austin GURNEY
Fumiko AXELROD
Tim HOEY
Sanjeev SATYAL
United States
United States
United States
United States
YAO, LEI
2018-08-2316079180REDIRECTING IMMUNE RESPONSESOncoMed Pharmaceuticals, Inc.Abandoned -- Incomplete Application (Pre-examination)US20190048094A1
Austin L. GURNEY
Cecile CHARTIER-COURTAUD
United States
United States
2018-05-1715777175PD-L1-BINDING AGENTS AND USES THEREOFOncomed Pharmaceuticals, Inc.Abandoned -- Incomplete Application (Pre-examination)US20180346571A1
Austin L. GURNEY
Ming-Hong XIE
United States
United States
2018-04-2515962728Methods and Monitoring of Treatment with a WNT Pathway InhibitorOncoMed Pharmaceuticals, Inc.Abandoned -- Failure to Respond to an Office ActionUS20190000970A1
Jakob DUPONT
Robert J. STAGG
United States
United States
GAMETT, DANIEL C
2018-02-2615755142COMBINATION THERAPY FOR TREATMENT OF DISEASEOncoMed Pharmaceuticals, Inc.Abandoned -- Failure to Respond to an Office ActionUS20180244783A1
Timothy Charles HOEY
Christopher Lamond MURRIEL
Jennifer Anne CAIN
United States
United States
United States
MOSELEY II, NELSON B
2018-02-0215749855IDENTIFICATION OF PREDICTIVE BIOMARKERS ASSOCIATED WITH WNT PATHWAY INHIBITORSOncoMed Pharmaceuticals, Inc.Abandoned -- Failure to Respond to an Office ActionUS20180223372A1
Ann M. KAPOUN
Chun ZHANG
United States
United States
YAO, LEI
2018-01-2415879113Method For Making Heteromultimeric MoleculesOncoMed Pharmaceuticals, Inc.Abandoned -- Failure to Respond to an Office ActionUS20180312581A1
Austin L. GURNEY
Aaron K. SATO
United States
United States
SANG, HONG
2017-12-2015849368LYMPHOTOXIN-BETA RECEPTOR-BINDING AGENTS, TARGETING ANTIBODIES, AND USES THEREOFOncoMed Pharmaceuticals, Inc.Abandoned -- Failure to Respond to an Office ActionUS20180222958A1
Austin L. GURNEY
Inkyung Park
Fumiko Takada Axelrod
United States
United States
United States
MCCOLLUM, ANDREA K
2017-11-2015817998COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CANCEROncoMed Pharmaceuticals, Inc.Abandoned -- Failure to Respond to an Office ActionUS20180222997A1
Austin L. Gurney
John Lewicki
Sanjeev H. Satyal
Timothy Charles Hoey
United States
United States
United States
United States
DUFFY, BRADLEY
2017-10-3015797182IMMUNOTHERAPY WITH BINDING AGENTSOncoMed Pharmaceuticals, Inc.Abandoned -- Failure to Respond to an Office ActionUS20180214526A1
Austin L. GURNEY
Fumiko Takada AXELROD
United States
United States
YU, MISOOK
2017-07-0715643676Compositions and Methods for Diagnosing and Treating CancerOncoMed Pharmaceuticals, Inc.Abandoned -- Failure to Respond to an Office ActionUS20180094040A1
AUSTIN GURNEY
John LEWICKI
Sanjeev H. SATYAL
Timothy HOEY
United States
United States
United States
United States
LANDSMAN, ROBERT S
2017-06-2315631259COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING CANCEROncoMed Pharmaceuticals, Inc.Abandoned -- Failure to Respond to an Office ActionUS20180099047A1
Austin L. GURNEY
Aaron SATO
United States
United States
HUFF, SHEELA JITENDRA
2017-05-3115531876Combination Therapy For Treatment of CancerOncoMed Pharmaceuticals, Inc.Abandoned -- Failure to Respond to an Office ActionUS20170266276A1
Austin L. GURNEY
Wan-Ching YEN
Timothy Charles HOEY
United States
United States
United States
STOICA, ELLY GERALD
2017-04-0515480081POLYNUCLEOTIDES ENCODING ANTI-RSPO2 ANTIBODIESOncoMed Pharmaceuticals, Inc.Abandoned -- Failure to Pay Issue FeeUS20170298143A1
Austin L. GURNEY
Fumiko Takada AXELROD
Timothy Charles HOEY
Cecile CHARTIER-COURTAUD
United States
United States
United States
United States
LOCKARD, JON MCCLELLAND
2017-02-2415506424COMBINATION THERAPY FOR TREATMENT OF CANCEROncoMed Pharmaceuticals, Inc.Abandoned -- Failure to Respond to an Office ActionUS20170247465A1
Austin L. GURNEY
Wan-Ching YEN
United States
United States
LANDSMAN, ROBERT S
2017-02-2415441700Compositions and Methods for Treating and Diagnosing CancerOncoMed Pharmaceuticals, Inc.Abandoned -- Failure to Respond to an Office ActionUS20170296658A1
Austin L. GURNEY
United States
HUFF, SHEELA JITENDRA
2017-02-2215439288RSPO3 Binding Agents and Uses ThereofOncoMed Pharmaceuticals, Inc.Abandoned -- Failure to Respond to an Office ActionUS20170267776A1
Austin L. GURNEY
Christopher J. Bond
United States
United States
ROARK, JESSICA HOPE
2017-02-1415503928RSPO1 BINDING AGENTS AND USES THEREOFOncoMed Pharmaceuticals, Inc.Abandoned -- Failure to Respond to an Office ActionUS20170247437A1
Austin L. GURNEY
United States
ALLEN, MICHAEL D
2017-02-0115421635Methods and Monitoring of Treatment With A DLL4 AntagonistONCOMED PHARMACEUTICALS, INC.Abandoned -- Failure to Respond to an Office ActionUS20170299598A1
Steven Eugene BENNER
Robert Joseph Stagg
Jakob Dupont
United States
United States
United States
STOICA, ELLY GERALD
2017-01-1315406229Wnt Antagonists and Methods of Treatment and ScreeningOncoMed Pharmaceuticals, Inc.Abandoned -- Failure to Respond to an Office ActionUS20170218041A1
Sanjeev H. SATYAL
Satyajit Sujit Kumar Mitra
Austin L. Gurney
United States
United States
United States
DENT, ALANA HARRIS
2016-12-1915383433FRIZZLED-BINDING AGENTS AND USES THEREOFOncoMed Pharmaceuticals, Inc.Abandoned -- Failure to Respond to an Office ActionUS20170234854A1
AUSTIN L. GURNEY
AARON KEN SATO
FUMIKO TAKADA AXELROD
TIMOTHY CHARLES HOEY
SANJEEV H. SATYAL
SATYAJIT SUJIT KUMAR MITRA
United States
United States
United States
United States
United States
United States
KAUFMAN, CLAIRE M
2016-11-1015310132IMMUNOTHERAPY WITH BINDING AGENTSONCOMED PHARMACEUTICALS, INC.Abandoned -- Failure to Respond to an Office ActionUS20170267758A1
Austin L. GURNEY
Ming-hong XIE
James Gordon PORTER
United States
United States
United States
NATARAJAN, MEERA
2016-10-2015298527NOTCH BINDING AGENTS AND ANTAGONISTS AND METHODS OF USE THEREOFOncoMed Pharmaceuticals, Inc.Abandoned -- Failure to Respond to an Office ActionUS20170198031A1
Austin L. GURNEY
Timothy Charles HOEY
Edward Thein Htun van der HORST
Aaron Ken SATO
Yuan Ching LIU
Maureen Fitch BRUHNS
John A. LEWICKI
United States
United States
United States
United States
United States
United States
United States
BUNNER, BRIDGET E
2016-10-1215291334NOTCH1 RECEPTOR BINDING AGENTS AND METHODS OF USE THEREOFOncoMed Pharmaceuticals, Inc.Abandoned -- Failure to Respond to an Office ActionUS20170183405A1
Austin L. GURNEY
Timothy Charles Hoey
Maureen Fitch Bruhns
Fumiko Takada Axelrod
United States
United States
United States
United States
BUNNER, BRIDGET E
2016-09-3015301161NOTCH3 ANTIBODIES AND USES THEREOFONCOMED PHARMACEUTICALS, INC.Abandoned -- Failure to Respond to an Office ActionUS20170023576A1
Belinda CANCILLA
United States
BUNNER, BRIDGET E
2016-09-0615123864METHODS FOR TREATING CANCER WITH NOTCH1 ANTIBODIESONCOMED PHARMACEUTICALS, INC.Abandoned -- Failure to Pay Issue FeeUS20170022289A1
Jakob Dupont
Ann M. Kapoun
Belinda Cancilla
United States
United States
United States
BUNNER, BRIDGET E
2016-06-2315107841Immunotherapy with Binding AgentsONCOMED PHARMACEUTICALS, INC.Abandoned -- Failure to Respond to an Office ActionUS20170044268A1
Austin L. GURNEY
Ming-Hong XIE
Julie Michelle RODA
United States
United States
United States
HADDAD, MAHER M
2016-06-0215101242Identification of Predictive Biomarkers Associated With WNT Pathway InhibitorsONCOMED PHARMACEUTICALS, INC.Abandoned -- Failure to Pay Issue FeeUS20160304968A1
ANN M. KAPOUN
CHUN ZHANG
United States
United States
REDDIG, PETER J
2016-05-2715167510Compositions and Methods for Diagnosing and Treating CancerOncoMed Pharmaceuticals, Inc.Abandoned -- Failure to Respond to an Office ActionUS20160367667A1
Austin GURNEY
Fumiko AXELROD
Tim HOEY
Sanjeev SATYAL
United States
United States
United States
United States
YAO, LEI
2016-04-1315097631Methods for Treating Cancer with DLL4 AntagonistsOncoMed Pharmaceuticals, Inc.Abandoned -- Failure to Respond to an Office ActionUS20160324961A1
Robert Joseph STAGG
Steven Eugene BENNER
John LEWICKI
Timothy Charles HOEY
United States
United States
United States
United States
HALVORSON, MARK
2016-03-1515070373METHODS AND MONITORING OF TREATMENT WITH A DLL4 ANTAGONISTOncoMed Pharmaceuticals, Inc.Abandoned -- Failure to Respond to an Office ActionUS20160334423A1
Steven Eugene BENNER
Robert Joseph Stagg
Jakob Dupont
United States
United States
United States
STOICA, ELLY GERALD
2016-01-2115003322FRIZZLED-BINDING AGENTS AND USES THEREOFOncoMed Pharmaceuticals, Inc.Abandoned -- Failure to Respond to an Office ActionUS20160326259A1
Austin L. Gurney
Aaron Ken Sato
Fumiko Takada Axelrod
Timothy Chartes Hoey
Sanjeev H. Satyal
Satyajit Sujit Kumar Mitra
Canada
United States
Canada
United States
United States
United States
STOICA, ELLY GERALD
2016-01-1214993775METHODS OF TREATING NEUROENDOCRINE TUMORS USING FRIZZLED-BINDING AGENTSOncoMed Pharmaceuticals, Inc.Abandoned -- Failure to Respond to an Office ActionUS20160235844A1
Robert Joseph Stagg
Jakob Dupont
United States
United States
GAMETT, DANIEL C
2015-12-0814962127METHODS FOR TREATING CANCERS COMPRISING K-RAS MUTATIONSOncoMed Pharmaceuticals, Inc.Abandoned -- Failure to Respond to an Office ActionUS20160243223A1
Timothy C. HOEY
Wan-Ching Yen
Marcus M. Fischer
United States
United States
United States
DUFFY, BRADLEY
2015-10-3014928271Combination Therapy For Treatment Of DiseaseOncoMed Pharmaceuticals, Inc.Abandoned -- Failure to Respond to an Office ActionUS20160176962A1
Christopher Lamond Murriel
Timothy Charles Hoey
Austin L. Gurney
Julie Michelle Roda
Minu K. Srivastava
Inkyung Park
Jakob Dupont
United States
United States
United States
United States
United States
United States
United States
BUNNER, BRIDGET E
2015-09-1414852916MET-BINDING AGENTS AND USES THEREOFOncoMed Pharmaceuticals, Inc.Abandoned -- Failure to Respond to an Office ActionUS20160137744A1
Austin L. GURNEY
Ming-Hong Xie
Christopher John Bond
United States
United States
United States
HUFF, SHEELA JITENDRA
2015-09-1414776262MET-BINDING AGENTS AND USES THEREOFONCOMED PHARMACEUTICALS, INC.Abandoned -- Failure to Respond to an Office ActionUS20160319034A1
Austin L. GURNEY
Ming-Hong XIE
Christopher John BOND
United States
United States
United States
NATARAJAN, MEERA
2015-09-1414776259NOTCH3 POLYNUCLEOTIDE SEQUENCESONCOMED PHARMACEUTICALS, INC.Abandoned -- Failure to Respond to an Office ActionUS20160030561A1
Timothy Charles HOEY
Chun ZHANG
Ann M. KAPOUN
United States
United States
United States
BUNNER, BRIDGET E
2015-06-0314358331Human Notch Receptor Mutations and Their UseOncoMed Pharmaceuticals, Inc.Abandoned -- Failure to Respond to an Office ActionUS20150316552A1
Jennifer Anne Cain
Min Wang
Ann M. Kapoun
Timothy C. Hoey
United States
United States
United States
United States
LI, RUIXIANG
2015-04-1414435589Methods of Treating Ocular DiseasesOncoMed Pharmaceuticals, Inc.Abandoned -- Failure to Respond to an Office ActionUS20150368329A1
Paul James HASTINGS
United States
SPECTOR, LORRAINE
2015-03-1914429497Methods of Treating Hematological Malignancies with Notch1 AntibodiesOncomed Pharmaceuticals, Inc.Abandoned -- Failure to Respond to an Office ActionUS20150232570A1
Timothy C. Hoey
Ann M. Kapoun
Min Wang
Tracy Tzu-Ling Tang Lin
Jennifer Anne Cain
Jakob Dupont
United States
United States
United States
United States
United States
United States
BUNNER, BRIDGET E
2014-06-0514362991Combination Therapy for Treatment of CancerOncoMed Pharmaceuticals, Inc.Abandoned -- Failure to Respond to an Office ActionUS20150132301A1
Timothy C. Hoey
Christopher Lamond Murriel
United States
United States
HUFF, SHEELA JITENDRA
2014-01-0614148556Compositions and Methods for Diagnosing and Treating CancerOncoMed Pharmaceuticals, Inc.Abandoned -- Failure to Respond to an Office ActionUS20140186342A1
John LEWICKI
Austin Gurney
Sanjeev Satyal
United States
United States
United States
CARTER, SANDRA DILLAHUNT
2013-10-3114068890Methods and Monitoring of Treatment with a DLL4 AntagonistONCOMED PHARMACEUTICALS , INC.Abandoned -- Failure to Respond to an Office ActionUS20140227252A1
STEVEN EUGENE BENNER
ROBERT JOSEPH STAGG
JAKOB DUPONT
United States
United States
United States
STOICA, ELLY GERALD
2013-06-0613911756Binding Agents That Modulate the Hippo Pathway and Uses ThereofOncoMed Pharmaceuticals, Inc.Abandoned -- Failure to Respond to an Office ActionUS20140056890A1
Austin L. GURNEY
Cecile Chartier-Courtaud
United States
United States
HADDAD, MAHER M
2013-05-1613895543METHODS FOR TREATING CANCER WITH NOTCH2/3 ANTIBODIESOncoMed Pharmaceuticals, Inc.Abandoned -- Failure to Respond to an Office ActionUS20130323266A1
Timothy Charles HOEY
John A. Lewicki
Wan-Ching Yen
Jakob Dupont
United States
United States
United States
United States
HALVORSON, MARK
2013-05-1013891815Compositions and Methods for Diagnosing and Treating CancerOncoMed Pharmaceuticals, Inc.Abandoned -- Failure to Respond to an Office ActionUS20130316450A1
Edward Thein Htun VAN DER HORST
Aaron Ken SATO
United States
United States
SANG, HONG
2013-03-1313800801Frizzled-Binding Agents And Uses ThereofOncoMed Pharmaceuticals, Inc.Abandoned -- Failure to Respond to an Office ActionUS20130295106A1
Austin L. Gurney
Aaron Ken Sato
Fumiko Takada Axelrod
Timothy Charles Hoey
Sanjeev H. Satyal
Satyajit Sujit Kumar Mitra
United States
United States
United States
United States
United States
United States
KAUFMAN, CLAIRE M